






Advanced risk management with the <u>Clinical Decision System</u>



Présentation to the Norvegian Directorate for E-health and the Norvegian Centre for E-health Research

French-Norwegian E-health meet-up, Nov 23rd francois.versini@keenturtle.com 33(0) 6 8275 3377



irectorate of eHealth



Systematic detection of risks related to drug prescriptio for your patients in real life.

- Truly relevant alerts
- Scoring and prioritisation of high-risk patients

# Disruption in Data Intelligence... for a disruption

in Medication risk detection and management

... and many other uses



### **DRUG-RELATED IATROGENY**

**Real-time**, relevant, personalised and contextualised alerts



+40 hospitals/clinics in France, Belgium and Switzerland



+10000 beds




+300 000 stays / year



thousands of serious problems avoided

### **Multiple Digitalized Uses**



# With keenturtle


healthcare professionals benefit from :

+ personalized and contextualized data,

which are exploited by + customizable algorithms

for more security and more efficiency in optimized patient care





#### PharmaClass®

changes the game by empowering the pharmacist to eliminate medication errors

### SmartBlend®

changes the game with interfaces and hubs capable of retrieving a large span of data, and normalizing it

### RuleStore®, MedAllIn®

changes the game with more complete and upto-date information more sensitive, specific rules

# GHT Sud Lorraine







# **EAHP**

PHARMACEUTICAL
ALGORITHMS
TARGETING
ANTITHROMBOTIC
THERAPY: IMPACT OF
A CLINICAL DECISION
SUPPORT IN PATIENT
SAFETY



An observational prospective study has been ongoing from January 2019 to September 2020 in 2 facilities (1600 beds).

Twenty-three about 135 pharmaceutical algorithms encoded in Pharmaclass® detected patients with an antithrombotic related problem.


Guidelines structure the pharmaceutical analysis of selected DRPs analyzed from anamnesis to Pharmaceutical Interventions' transmission (PI).


- Heparin induced thrombopenia Side effect Hemorrhage Thrombosis
- Unfractionnated heparin & GFR > 30 mL/min
  No-compliance with standards Hemorrhage
  Unfractionnated heparin overdosing
- Hemorrhage
   Heparinotherapy and obesity Drug Underdosing 
   Thromboembolic event
- Unfractionnated heparin Underdosing Thrombosis
- Low molecular weight heparin & renal insufficiency Contraindication Hemorrhage
- Low molecular weight heparin Overdosing Hemorrhage
- Prophylactic anticoagulation under Low molecular weight heparin & thin patient Overdosing Hemorrhage
- Curative anticoagulation & Intramuscular injection Inappropriate route of administration Hemorrhage

- Direct anticoagulant & renal insufficiency Contraindication Hemorrhage
- Direct anticoagulant & Heparin Contraindication Hemorrhage
- Miconazol & Direct anticoagulant Drug interaction Hemorrhage
  Xaban Drug interaction Hemorrhage
- Apixaban risk factors Overdosing Hemorrhage
- Apixaban Underdosing Thromboembolic event
- Rivaroxaban Overdosing Hemorrhage
- Dabigatran risk factors Overdosing Hemorrhage
- VKA & INR > 4.0 Overdosing Hemorrhage
   Ticagrelor or Prasugrel & Aspirin Litreater
- Ticagrelor or Prasugrel & Aspirin Untreated indication Thrombosis
- Anticoagulant or Antiplatelets Severe thrombopenia Contraindication Hemorrhage
- Anticoagulant and antiarrhythmic drug underdosing Inefficiency
- Heparin & VKA Drug not indicated Hemorrhage
   Direct anticoggulant & VKA Drug interaction
- Direct anticoagulant & VKA Drug interaction Hemorrhage

#### Results

The data are collected during 260 non-consecutive days. On 4121 alerts 1301 were about anticoagulant medications (31%) and 2820 about other medications (69%). DRP detection is better performed with algorithms' on anticoagulants than with the other one (1029 [79%] vs 1271 [45%]), because of fewer technical false positives.






Pharmacist issued 437 PI targeting antithrombotic medicines of which 266 PI (61%) were accepted by physician. On the other hand 1075 transmitted PI have resulted in 505 accepted PI (47%). The difference is statistically significant (X2=23.99; p<10-6). For both of the algorithms' sets the transmission way has the same importance: for the oral way, respectively 29% vs 27% (NS). And the acceptance rate is similar with 81% and 75% respectively (NS).



PATIENTS SUIVIS 80 NOMBRE D'ALERTES ALERTES EN COURS ALERTES TRAITÉES ALERTES NON LUES Afficher les filtres 13/04/2017 Criticité \*9/10 Morphine et GFR inférieur à 15 mL par minute [MORPHINandGFR15] Surveillance d'un médicament à risque au travers de la biologie [NIP000 Hôpital Universitaire Pit 00h00m00s Analyse nºmedbio 00023 du 06/04/2017 Ordonnance nºpresc 1800011 du 01/04/2017 △ [33914-3] Filtration glomérulaire corrigée/1,73m2 **△** [3400921879599] MORPHINE (CHLORHYDRATE) calculée [Volume relatif/Temps] Sérum/Plasma; RENAUDIN 10 MG/ML 1 BOITE DE 1, 100 ML EN POCHE, Numérique ; Formule MDRD, Valeur mesurée 13.4 SOLUTION INJECTABLE, Présence dans la prescription Plus de détails En cours de traitement 21/04/2017 Criticité \*9/10 Prévention de l'hyponatrémie due à d'autres antidépresseurs non spécifiés pendant leur utilisation thérapeutique Y49\_2 [IATRO\_Y49.2.4] Détection d'une iatrogénie supposée [NIP\_00 00h00m00s Analyse n°ANAL\_0029 du 01/04/2017 Age 89 ans △ [2951-2] Sodium [Moles/Volume] Sérum/Plasma; Numérique, Valeur mesurée 15.0 Ordonnance nºORDO 0029 du 01/04/2017 In just a few clicks, the pharmacy team receives relevant alerts, △ [3400922394787] ESCITALOPRAM SANDOZ 5MG 1 prioritized thanks to the accuracy of the data taken into account = 'Control Tower' to deal with a maximum number of risks and focus

expertise on the most important risks.



Keenturtle has been chosen as reference Al for pharmaceuticals in Europe,

being the only one able to be the early pilot of what will become mandatory by 2025 by the 'Al Act' due out in February 2023.





The Human Guarantee principle of AI and digital health, introduced and carried by Ethik-IA since 2017, has been recognized in France in the CCNE texts 129 and 130 and in Article 17 of the Bioethics Law.

This methodology of the Human Guarantee has been included in the draft **regulation on Al of the European Commission** in articles 14 and 29, which should be **voted in February 2023, for application within two years**.

The resulting AI Human Guarantee principle will require all users and developers of AI solutions in health to:

- The implementation of prior information to the patient on the use of AI in his or her care;
- The deployment of a human supervision of the AI solution "in real life" in conditions of traceability implemented under the control and supervision of the institutions of each country, in particular the CNIL and the HAS in France.

# Keenturtle at **PariSanté** Campus

Digitizing according to the new possibilities



## **Multiple Digitalized Uses:**

Tooling of a specific process: Pharmaceutical Analysis in the hospital City-hospital territory perspective (EHPAD, Officines, MonEspaceSanté, ...)

Provision of these 'bricks' to the innovations supported

- by PariSante campus
- in Health system in France, Belgium, Switzerland
- In synergy with
- And in Norway?







- > A French champion of Al in Health
  - > Leveraging the eHealth ecosystem



A unique body of science to systematically detect and parameterize according to the targeted policies



# **Data Intelligence brick:**

A patient profile and a use of stan dards without equivalent: collectio n of data made usable within the h ospital and then on the city-hospit al territory
















Advanced risk management with the <u>Clinical Decision System</u>



Présentation to the Norvegian Directorate for E-health and the Norvegian Centre for E-health Research

French-Norwegian E-health meet-up, Nov 23rd francois.versini@keenturtle.com 33(0) 6 8275 3377



irectorate of eHealth